-
Zytiga OKed as prostate cancer treatment
HORSHAM, Pa. — The Food and Drug Administration has approved a new treatment for prostate cancer made by Johnson & Johnson.
Centocor Ortho Biotech, J&J’s biotech subsidiary, announced Thursday the approval of Zytiga (abiraterone acetate), a daily pill for use in combination with the corticosteroid prednisone for treating castration-resistant prostate cancer that has spread to other parts of the body in men who have received prior chemotherapy with Sanofi-Aventis’ Taxotere (docetaxel).
-
NACDS, NCPA express support for Military Retirees Health Care Protection Act
ALEXANDRIA, Va. — The National Association of Chain Drug Stores and the National Community Pharmacists Association announced on Friday that they have issued a letter to Rep. Walter B. Jones, R-N.C., expressing pharmacy's support for H.R. 1092, the Military Retirees Health Care Protection Act, which would help preserve Tricare beneficiaries' access to pharmacy-based healthcare services.
The bill, introduced by Jones, prohibits increases to retail pharmacy co-payments.